AI in Drug Trials, Pfizer's Innovations, and NVIDIA's CoreWeave Partnership

episode

The AI News Daily Brief not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

NPR News: 09-27-2026 4AM EDT 5 min · 27 Sep 2026 · NPR News Now

4AM ET 09/27/2026 Newscast 3 min · 27 Sep 2026 · Fox News Hourly Update

Day 270: God's Favor with Ezra (2026) 27 min · 27 Sep 2026 · The Bible in a Year (with Fr. Mike Schmitz)

NPR News: 09-27-2026 3AM EDT 5 min · 27 Sep 2026 · NPR News Now

3AM ET 09/27/2026 Newscast 3 min · 27 Sep 2026 · Fox News Hourly Update

Lil’ Peep (Rewind): A new hip-hop and emo fusion; trap beats, tender lyrics, too much Xanax and an overdose that’s still mysterious. 41 min · 27 Sep 2026 · DISGRACELAND

Report any issue

Source

Recorded26 Jan 2026

Publisherfeeds.podcastai.com ↗

Handlerec:15516926

Show notes

In this episode, Bob introduces the role of AI in drug development, particularly its impact on streamlining clinical trials. The discussion then shifts to Pfizer's recent innovations in AI, which have reportedly reduced the time to market for new drugs. Bob highlights Recursive's advancements in self-improving AI systems and their recent funding achievements. Attention is given to NVIDIA's collaboration and investment in CoreWeave's AI factories, which aim to bolster AI infrastructure. The episode concludes with closing remarks and an outlook on future developments in AI, emphasizing the importance of these advancements in shaping the industry.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in